Financial Data and Key Metrics Changes - As of December 31, GAAP book value was $13.20 per share, and economic book value was $13.75 per share, both showing modest increases from the end of September [14] - For the fourth quarter, MFA generated GAAP earnings of $54.3 million, or $0.42 per basic common share, with net interest income at $55.5 million, a slight decline from $56.8 million in the previous quarter [15][16] - Distributable earnings for the fourth quarter were approximately $27.8 million, or $0.27 per share, an increase from $0.20 per share in the third quarter [18] Business Line Data and Key Metrics Changes - In the fourth quarter, MFA acquired $1.9 billion of loans and securities, including $1.2 billion of agencies, $443 million of non-QM loans, and $226 million of new business purpose loans [10] - The agency book grew by over 50% to $3.3 billion during the quarter, with a focus on low payout spec pools [20] - Lima One originated $226 million of new loans in the fourth quarter, including various types of loans such as new construction and rehab loans [22] Market Data and Key Metrics Changes - The Bloomberg US Aggregate Index was up 7.3% in 2025, following a decline of 7.1% over the previous three years [5] - Treasury rates declined, with 2-year yields dropping 77 basis points and 10-year yields dropping by 39 basis points [5] - The delinquency rate across the entire loan portfolio ended the year at just over 7%, down from 7.5% a year ago [23] Company Strategy and Development Direction - MFA is focused on increasing earnings and growing return on equity (ROE) through strategic initiatives, including deploying excess cash into target assets [9] - The company is excited about 2026, starting the year with favorable market conditions and government support for housing affordability [6][7] - MFA plans to relaunch multifamily lending and has made investments in technology and sales force to enhance operational efficiency [11][22] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the mortgage market due to lower rates, reduced volatility, and a positively sloped yield curve [6] - The company expects to see results from its strategic initiatives in 2026, with a focus on resolving delinquent loans and reducing general and administrative expenses [12][13] - Management anticipates that distributable earnings will reconverge with the common dividend in the latter half of 2026 [30] Other Important Information - MFA paid a common dividend of $0.36 for the fourth quarter and $1.44 for the full year, with approximately 40% of dividends treated as a tax-deferred return of capital [14] - The company has rolled out several technology platforms to enhance borrower experience and drive operational efficiencies [11] Q&A Session Summary Question: Can you talk about the run rate ROE on your EAD once loss provisions are through? - Management indicated that DE on a lossless basis is expected to be in the 8%-9% range, potentially reaching 10-11% in the back half of next year [29] Question: Can you discuss the re-entry into the multifamily market? - The company is targeting higher quality loans with larger unit sizes and an originate-to-sell model to capture fees [31] Question: How do you think about the potential deals that could be called? - Management expects to unlock $50 million-$100 million of capital that can be redeployed, with several deals anticipated in the coming quarters [36] Question: How should we think about capital allocation going forward? - The expectation is to initially increase investments in the agency portfolio before transitioning to non-QM and BPL asset classes as capital is freed up [40] Question: What are your expectations for margins and total volumes throughout the year? - The company anticipates healthy spreads and significant growth potential, particularly in the back half of the year as new channels come online [54]

EMPIRE STATE REALTY TRUST Investor Presentation February 2026 North Sixth Street Collect Multi-Purpose Space at ESB Williamsburg, Brooklyn Rooftop and Penthouse Lounge at 501 Seventh Ave Sol de Janeiro at One Grand Central Place 34th Street Empire Lounge at ESB CLA at One Grand Central Place Empire State Empire State Building REALTY TRU Contents ESRT's Transformation Quarterly Highlights ESRT Overview ESRT Property Sector Highlights Key Takeaways Appendix 2 | 38 RE STATE REALTY TRUST ESRT's Transformation 3 ...

Select Water Solutions (NYSE:WTTR) Q4 2025 Earnings call February 18, 2026 11:00 AM ET Speaker10Greetings, and welcome to the Select Water Solutions fourth quarter earnings conference call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to intro ...

Devon Energy (NYSE:DVN) Q4 2025 Earnings call February 18, 2026 11:00 AM ET Speaker12Welcome to Devon Energy's fourth quarter 2025 conference call. At this time, all participants are in listen-only mode. This call is being recorded. I'd now like to turn the call over to Mr. Chris Carr, Director of Investor Relations. You may begin.Speaker3Good morning, and thank you for joining us on the call today. Last night, we issued Devon's fourth quarter and year-end 2025 earnings release and presentation materials. T ...

Sonic Automotive (NYSE:SAH) Q4 2025 Earnings call February 18, 2026 11:00 AM ET Speaker11Good morning, and welcome to the Sonic Automotive fourth quarter 2025 earnings conference call. This conference call is being recorded today, Wednesday, February 18, 2026. Presentation materials which accompany management's discussion on the conference call can be accessed at the company's website at ir.sonicautomotive.com. At this time, I would like to refer to the Safe Harbor statement under the Private Securities Lit ...

British American Tobacco (NYSE:BTI) 2026 Conference February 18, 2026 11:00 AM ET Company ParticipantsDavid Waterfield - PresidentTadeu Marroco - CEONone - Video NarratorModeratorOkay. Hi, everyone. Thanks for joining us today. It's a pleasure to welcome British American Tobacco to CAGNY this year. Joining us today are Tadeu Marroco, Chief Executive Officer, and David Waterfield, President of Reynolds American. Also, please join me in thanking them for their sponsorship of the lunch following their presenta ...

Summary of CRISPR Therapeutics Conference Call Company Overview - **Company**: CRISPR Therapeutics (NasdaqGM:CRSP) - **Event**: Virtual Oncology Leadership Summit - **Date**: February 18, 2026 Key Points Industry Focus - CRISPR Therapeutics is engaged in multiple disease areas, with a strong focus on oncology, cardiovascular diseases, autoimmune diseases, and Type 1 diabetes [3][4] Oncology Programs - **ZugoCell (formerly CTX112)**: A next-generation allogeneic CAR-T therapy targeting CD19, designed to improve potency and safety compared to earlier generations [4][5] - **Allogeneic CAR-T**: Made from healthy donor-derived cells, with advanced edits to enhance efficacy and safety, aiming for autologous-like performance [5][6] Key Edits in ZugoCell - **Beta-2M Knockout**: Prevents immune system from recognizing allogeneic cells as foreign, enhancing persistence [8][9] - **RGNASE1 Knockout**: Retains a naive T cell phenotype, allowing for better expansion and reduced exhaustion [10][11] - **TGF-beta Receptor 2 Knockout**: Prevents exhaustion of CAR-T cells, enhancing potency [10][11] Clinical Strategy - **Autoimmune Diseases**: Rapidly enrolling patients for indications like lupus, myositis, and scleroderma, with plans to expand further [17][18] - **Oncology**: Aiming for high complete response (CR) rates and durability, with initial CR rates for ZugoCell reaching nearly 70% [20][21] Regulatory Pathway - Parallel development in oncology and autoimmune indications, with discussions with regulators expected to guide future trials [27][28] Pricing Strategy - Targeting a price point of around $200K for allogeneic CAR-T therapies, significantly lower than current autologous therapies priced at $350K-$400K [52][53] In Vivo CAR-T Development - Developing both transient and permanent CAR-T therapies using LNP-mediated delivery, with a focus on safety and efficacy [54][55] - Permanent CARs could potentially eliminate tumors with a single injection, offering a significant advancement in oncology [56][57] Market Opportunities - Significant potential in both U.S. and international markets, particularly in regions where autologous therapies are not feasible due to cost and availability [48][49] Future Directions - Continued focus on data collection and analysis in both oncology and autoimmune spaces, with a strong emphasis on achieving long-term remissions and safety [31][32][39] Conclusion - CRISPR Therapeutics is positioned to make significant advancements in both oncology and autoimmune therapies through innovative CAR-T technologies, with a clear strategy for regulatory approval and market entry.

Financial Data and Key Metrics Changes - Consolidated revenue increased 17% to over $2.1 billion in Q4 2025, marking a new record for the fourth quarter and the first quarter to exceed $2 billion [5][20] - Full year consolidated revenue rose 15% to $7.25 billion, a new annual record, up nearly $1 billion from 2024 [6][22] - Gross margin for Q4 was 59.2%, comparable to the prior year, while operating margin expanded by 60 basis points to 28.9% [5][20] - Record full-year operating income reached nearly $1.9 billion, up 18% year-over-year, with an operating margin of 25.9% [7][22] Business Segment Data and Key Metrics Changes - Fitness segment revenue increased 33% to $2.36 billion, driven by wearables, with operating income up 50% year-over-year to $726 million [10][11] - Outdoor segment revenue grew 5% to $2.05 billion, primarily from adventure watches, with operating income of $690 million [12][14] - Aviation segment revenue rose 13% to $987 million, with operating income increasing 22% to $257 million [15] - Marine segment revenue increased 10% to $1.18 billion, with operating income of $251 million [16] - Auto OEM segment revenue grew 9% to $665 million, but operating loss was $49 million for the year [18][19] Market Data and Key Metrics Changes - In Q4, the Americas region achieved strong double-digit growth of 21%, with quarterly revenue exceeding $1 billion for the first time [23] - For the full year, EMEA region grew by 18%, Americas by 40%, and APAC by 12% [23] Company Strategy and Development Direction - The company focuses on market diversification and creating superior products essential to customers' lives, which has been a successful strategy since its inception [6] - The company anticipates 2026 to be another year of strong growth, expecting revenue to increase approximately 9% to $7.9 billion [8][27] - A $500 million share repurchase program was approved, effective through December 2028, alongside a proposed annual dividend increase of 17% [9][25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating supply chain challenges and highlighted strong relationships with suppliers [8][9] - The company is optimistic about continued growth in the fitness segment, driven by demand for current products and new introductions [11][33] - Management noted that the overall market for wearables is on a steady growth path, with Garmin gaining market share [78] Other Important Information - The company plans to shift R&D resources from the auto OEM segment to accelerate product development in other segments [40] - The Truemed collaboration allows customers to use HSA and FSA funds for Garmin products, becoming a significant sales channel [59] Q&A Session Summary Question: Impact of memory costs on 2026 guidance - Management acknowledged pressure on memory costs but did not quantify the impact, emphasizing overall cost efficiency across the BOM [30][31] Question: Factors contributing to wearables growth - Growth was primarily volume-driven, with minor impacts from ASP; management expects continued momentum in 2026 [32][33] Question: Future of auto OEM business - Management noted that projections were based on automotive OEM partners' assumptions, which have since changed; they are focusing on achieving scale and innovation [39] Question: Growth opportunities in aviation - Management confirmed that projects like the Black Hawk helicopter modernization represent growth opportunities, leveraging commercial products for military applications [48][90] Question: Update on Connect Plus uptake - Management reported high conversion rates for the nutrition feature added to Connect Plus, indicating strong customer interest [49] Question: Global wearables market trends - Management believes the overall wearables market is experiencing steady growth, with Garmin gaining market share [78] Question: Marine industry outlook - Management sees a healthy marine market with active boat shows and demand for larger boats, contributing to growth [81]

Trane Technologies (NYSE:TT) 2026 Conference February 18, 2026 10:30 AM ET Company ParticipantsChris Kuehn - EVP and CFODave Regnery - Chairman and CEOConference Call ParticipantsNone - AnalystModeratorGet started again. We're super excited to have Trane Technologies with us. Again, a mainstay of our conference, and we appreciate it. We've got Dave Regnery, who is the Chairman and CEO of Trane, and Chris Kuehn, who is the EVP and CFO. So Dave, as I walk over, I think I ask you this question every year, but, ...

Garmin (NYSE:GRMN) Q4 2025 Earnings call February 18, 2026 10:30 AM ET Company ParticipantsCliff Pemble - President and CEODoug Boessen - CFO and TreasurerIvan Feinseth - Chief Investment Officer and Director of ResearchTeri Seck - Director of Investor RelationsConference Call ParticipantsBen Bollin - Partner and Senior Equity Research AnalystDavid MacGregor - President and Senior Equity Research AnalystErik Woodring - Executive Director and Equity AnalystJoseph Cardoso - VP and Equity Research AnalystNoah ...